Papers/PMID:37333786
Efficacy of resveratrol in women with polycystic ovary syndrome: a systematic review and meta-analysis of randomized clinical trials.
The Pan African medical journal2023The record
7 findings · 1 compound · 7 endpoints · 6 null
What it reported
How to read these marksWhat moved
1 finding
resveratrol — decreases total testosterone
StrongEvidence strength: strong. Randomised human trials or their synthesis, with the effect's size and interval recorded and no recorded weakness outstanding.Finding“The pooled effect estimate indicated that resveratrol significantly reduced the level of testosterone, compared with the placebo (SMD = -0.40; 95% CI [-0.71, -0.10], P = 0.009).”
Quoted verbatim from Efficacy of resveratrol in women with polycystic ovary syndrome: a systematic review and meta-analysis of randomized clinical trials.. - Study
- meta-analysis
- Participants
- 169
- Dose
- 800, 1000 or 1500 mg/day oral resveratrol
- Population
- Women with polycystic ovary syndrome; 3 of 4 pooled RCTs, resveratrol vs placebo
Effect -0.4 standardised mean difference, 95% CI -0.71 to -0.1
Efficacy of resveratrol in women with polycystic ovary syndrome: a systematic review and meta-analysis of randomized clinical trials.2023PMID:37333786Permalink
What did not
6 findings
resveratrol — no detected effect on HDL cholesterol
StrongEvidence strength: strong. Randomised human trials or their synthesis, with the effect's size and interval recorded and no recorded weakness outstanding.FindingNull resultreplicated ×2“The pooled effect estimate revealed no effect of resveratrol on HDL (MD = 0.24; 95% CI [-3.53, 4.00], P = 0.90).”
Quoted verbatim from Efficacy of resveratrol in women with polycystic ovary syndrome: a systematic review and meta-analysis of randomized clinical trials.. - Study
- meta-analysis
- Participants
- 108
- Population
- Women with PCOS, pooled across 2 RCTs (n=108: 54 per arm).
Effect 0.24 mean difference, 95% CI -3.53 to 4
Efficacy of resveratrol in women with polycystic ovary syndrome: a systematic review and meta-analysis of randomized clinical trials.2023PMID:37333786Permalink
resveratrol — no detected effect on triglycerides
StrongEvidence strength: strong. Randomised human trials or their synthesis, with the effect's size and interval recorded and no recorded weakness outstanding.FindingNull resultreplicated ×2“The pooled effect estimate revealed no effect of resveratrol on triglycerides (MD = -8.25; 95% CI [-37.25, 20.74], P = 0.58).”
Quoted verbatim from Efficacy of resveratrol in women with polycystic ovary syndrome: a systematic review and meta-analysis of randomized clinical trials.. - Study
- meta-analysis
- Participants
- 108
- Population
- Women with PCOS, pooled across 2 RCTs (n=108: 54 per arm).
Effect -8.25 mean difference, 95% CI -37.25 to 20.74
Efficacy of resveratrol in women with polycystic ovary syndrome: a systematic review and meta-analysis of randomized clinical trials.2023PMID:37333786Permalink
resveratrol — no detected effect on clinical pregnancy rate
StrongEvidence strength: strong. Randomised human trials or their synthesis, with the effect's size and interval recorded and no recorded weakness outstanding.FindingNull resultreplicated ×1“The pooled relative risk (RR) indicated no effect of resveratrol regarding clinical pregnancy rates (RR = 0.89; 95% CI [0.65, 1.23], P = 0.49).”
Quoted verbatim from Efficacy of resveratrol in women with polycystic ovary syndrome: a systematic review and meta-analysis of randomized clinical trials.. - Study
- meta-analysis
- Participants
- 101
- Population
- Women with PCOS, pooled across 2 RCTs (n=101: 50 resveratrol, 51 placebo).
Effect 0.89 risk ratio, 95% CI 0.65 to 1.23
Efficacy of resveratrol in women with polycystic ovary syndrome: a systematic review and meta-analysis of randomized clinical trials.2023PMID:37333786Permalink
resveratrol — no detected effect on total cholesterol (TC)
ModerateEvidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers.FindingNull resultreplicated ×1“The pooled effect estimate revealed no effect of resveratrol on cholesterol (MD = -5.91; 95% CI [-18.54, 6.72], P = 0.36).”
Quoted verbatim from Efficacy of resveratrol in women with polycystic ovary syndrome: a systematic review and meta-analysis of randomized clinical trials.. - Study
- meta-analysis
- Participants
- 108
- Dose
- 1000 or 1500 mg/day oral resveratrol
- Population
- Women with polycystic ovary syndrome; 2 pooled RCTs, resveratrol vs placebo
Effect -5.91 mean difference, 95% CI -18.54 to 6.72
Efficacy of resveratrol in women with polycystic ovary syndrome: a systematic review and meta-analysis of randomized clinical trials.2023PMID:37333786Permalink
resveratrol — no detected effect on LDL cholesterol
ModerateEvidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers.FindingNull result“The pooled effect estimate revealed no effect of resveratrol on LDL (MD = -2.03; 95% CI [-10.24, 6.18], P = 0.63).”
Quoted verbatim from Efficacy of resveratrol in women with polycystic ovary syndrome: a systematic review and meta-analysis of randomized clinical trials.. - Study
- meta-analysis
- Participants
- 108
- Population
- Women with PCOS, pooled across 2 RCTs (n=108: 54 per arm).
Effect -2.03 mean difference, 95% CI -10.24 to 6.18
Efficacy of resveratrol in women with polycystic ovary syndrome: a systematic review and meta-analysis of randomized clinical trials.2023PMID:37333786Permalink
resveratrol — no detected effect on C-reactive protein concentration
ModerateEvidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers.FindingNull result“The pooled effect estimate revealed no effect of resveratrol on the CRP (MD = 0.00; 95% CI [-1.31, 1.31], P = 1.00).”
Quoted verbatim from Efficacy of resveratrol in women with polycystic ovary syndrome: a systematic review and meta-analysis of randomized clinical trials.. - Study
- meta-analysis
- Participants
- 148
- Dose
- 800, 1000 or 1500 mg/day oral resveratrol
- Population
- Women with polycystic ovary syndrome; 3 pooled RCTs, resveratrol vs placebo
Effect 0 mean difference, 95% CI -1.31 to 1.31
Efficacy of resveratrol in women with polycystic ovary syndrome: a systematic review and meta-analysis of randomized clinical trials.2023PMID:37333786Permalink